期刊
BIOLOGICS-TARGETS & THERAPY
卷 8, 期 -, 页码 169-182出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/BTT.S41481
关键词
psoriasis; psoriatic arthritis; etanercept; biological therapy; tumor necrosis factor; safety
资金
- Abbott
- Allergan
- Celgene
- Eli Lilly
- Galderma
- Janssen
- LEO Pharma
- Novartis
- Novo Nordisk
- Pfizer
- Stiefel
- Syntrix Biosystems
- Wyeth
- Amgen
Psoriasis is a chronic, immune-mediated inflammatory disease affecting both the skin and joints. Approximately 20% of patients suffer a moderate to severe form of skin disease and up to 30% have joint involvement. Standard therapies for psoriasis include topical medications, phototherapy, and both oral systemic and biological therapies whereas therapies for psoriatic arthritis include nonsteroidal anti-inflammatory drugs followed by disease modifying antirheumatic drugs and/or tumor necrosis factor (TNF)-alpha inhibitors and interleukin-12/23p40 inhibitors. Treatment of both diseases is typically driven by disease severity. In the past decade, major advances in the understanding of the immunopathogenesis of psoriasis and psoriatic arthritis have led to the development of numerous biological therapies, which have revolutionized the treatment for moderate to severe plaque psoriasis and psoriatic arthritis. Anti-TNF-alpha agents are currently considered as first line biological therapies for the treatment of moderate to severe psoriasis and psoriatic arthritis. Currently approved anti-TNF-alpha agents include etanercept, adalimumab, and infliximab for psoriasis and psoriatic arthritis as well as golimumab and certolizumab for psoriatic arthritis. In this article, we aim to evaluate the long term safety and efficacy of etanercept in psoriasis and psoriatic arthritis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据